GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed Price. Currency in GBp
1,644.50-5.00 (-0.30%)
At close: 12:06 PM EDT
People also watch:
BP.LAZN.LRDSB.LVOD.LULVR.L
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1,645.00
Prev Close1,649.50
Bid1,632.50 x 187100
Ask1,650.00 x 336900
Day's Range1,639.50 - 1,653.00
52wk Range1,227.50 - 1,716.50
1y Target EstN/A
Market Cap79.68B
P/E Ratio (ttm)2,740.83
BetaN/A
Volume7,171,263
Avg Vol (3m)8,779,375
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Kiplinger5 hours ago

    7 Healthy Dividend Stocks for Quality and Security

    Looking for great growing dividend stocks? Then the healthcare sector has to be on your list.

  • TheStreet.comyesterday

    Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors

    Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.

  • Barrons.comyesterday

    Gilead Sciences: Don't Expect Perfection

    As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.